Literature DB >> 22323827

Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.

Christine M Lovly1, William Pao.   

Abstract

Mutated anaplastic lymphoma kinase (ALK) drives the development of multiple tumor types, and ALK tyrosine kinase inhibitors such as crizotinib have been validated as targeted therapeutics. Unfortunately, as with other oncogene-driven tumors, therapeutic resistance invariably develops. In Science Translational Medicine, two recent studies provide new insight into mechanisms of resistance to ALK tyrosine kinase inhibitors and possible strategies to overcome this resistance.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22323827     DOI： 10.1126/scitranslmed.3003728

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  46 in total

1.  Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study.

Authors:  S Vatrano; L Righi; T Vavalá; I Rapa; M Busso; S Izzo; S Cappia; A Veltri; M Papotti; G V Scagliotti; S Novello
Journal:  Target Oncol       Date:  2016-04       Impact factor: 4.493

2.  STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.

Authors:  Elisa Spaccarotella; Elisa Pellegrino; Manuela Ferracin; Cristina Ferreri; Giuditta Cuccuru; Cuiling Liu; Javeed Iqbal; Daniela Cantarella; Riccardo Taulli; Paolo Provero; Ferdinando Di Cunto; Enzo Medico; Massimo Negrini; Wing C Chan; Giorgio Inghirami; Roberto Piva
Journal:  Haematologica       Date:  2013-08-23       Impact factor: 9.941

3.  Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer.

Authors:  Lian-Xiang Luo; Ying Li; Yu-Zhen Niu; Yu-Wei Wang; Qian-Qian Wang; Xing-Xing Fan; Jia-Hui Xu; Liang Liu; Elaine Lai-Han Leung; Xiao-Jun Yao
Journal:  Medchemcomm       Date:  2017-08-25       Impact factor: 3.597

Review 4.  Detecting and targetting oncogenic fusion proteins in the genomic era.

Authors:  Monika A Davare; Cristina E Tognon
Journal:  Biol Cell       Date:  2015-04-07       Impact factor: 4.458

5.  Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.

Authors:  Lorena Lobo de Figueiredo-Pontes; Daisy Wing-Sze Wong; Vicky Pui-Chi Tin; Lap-Ping Chung; Hiroyuki Yasuda; Norihiro Yamaguchi; Sohei Nakayama; Pasi Antero Jänne; Maria Pik Wong; Susumu Soeda Kobayashi; Daniel Botelho Costa
Journal:  J Thorac Oncol       Date:  2014-02       Impact factor: 15.609

6.  Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.

Authors:  Monika A Davare; Anna Saborowski; Christopher A Eide; Cristina Tognon; Rebecca L Smith; Johannes Elferich; Anupriya Agarwal; Jeffrey W Tyner; Ujwal P Shinde; Scott W Lowe; Brian J Druker
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

7.  STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.

Authors:  Elisabet Cuyàs; Almudena Pérez-Sánchez; Vicente Micol; Javier A Menendez; Joaquim Bosch-Barrera
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

8.  Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

Authors:  Jim Sang; Jaime Acquaviva; Julie C Friedland; Donald L Smith; Manuel Sequeira; Chaohua Zhang; Qin Jiang; Liquan Xue; Christine M Lovly; John-Paul Jimenez; Alice T Shaw; Robert C Doebele; Suqin He; Richard C Bates; D Ross Camidge; Stephan W Morris; Iman El-Hariry; David A Proia
Journal:  Cancer Discov       Date:  2013-03-26       Impact factor: 39.397

Review 9.  Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents.

Authors:  Howard West; Geoffrey R Oxnard; Robert C Doebele
Journal:  Am Soc Clin Oncol Educ Book       Date:  2013

Review 10.  Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.

Authors:  Bin-Chi Liao; Chia-Chi Lin; Jin-Yuan Shih; James Chih-Hsin Yang
Journal:  Ther Adv Med Oncol       Date:  2015-09       Impact factor: 8.168
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.